Trial Profile
Pilot Analysis of the Effects of IFN alpha-2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes.
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Interferon alpha-2b (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 03 Aug 2017 Status changed from recruiting to discontinued.
- 08 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2019.
- 08 Jun 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2019.